Ferring Pharmaceuticals
AGA Offers New Guidance on FMT Therapies To Prevent C. diff
Treatment with FMT is effective for preventing recurrent Clostridioides difficile infection in adults with robust ...
APRIL 19, 2024
FDA Approves Adstiladrin, First Gene Therapy for Bladder Cancer
Adstiladrin is the first gene therapy for adults with high-risk bacillus Calmette-Guérin (BCG)-unresponsive ...
DECEMBER 21, 2022
FDA Approves Rebyota, the First Live Biotherapeutic Fecal Microbiota Product in the U.S.
RBX2660 (Rebyota, Ferring) is approved by the FDA for the prevention of recurrent Clostridioides difficile ...
DECEMBER 3, 2022
Novel Biotherapeutic Safe, Efficacious in Treating Recurrent CDI
RBX2660, a novel microbiota-based live biotherapeutic, consistently reduced rCDI among patients who are 65 years of ...
NOVEMBER 3, 2022
Investigational Biotherapeutic Effective Against C. difficile Up to 24 Months
The investigational microbiota-based live biotherapeutic, which was endorsed by the FDA's Vaccines and Related ...
OCTOBER 11, 2022
